EMA Authorised: Eucreas (vildagliptin;metformin hydrochloride) — Novartis Europharm Limited

View source ↗

Summary

The European Medicines Agency authorised Eucreas, a fixed-dose combination of vildagliptin and metformin, for Type 2 diabetes mellitus. The marketing authorizat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Eucreas (vildagliptin/metformin hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Novartis Europharm Limited. Decision date: 04/12/2025